NIH Clarifies mAbs Use Against COVID-19
The U.S. Centers for Disease Control and Prevention recently reported a rapid increase in the circulation of certain SARS-CoV-2 Omicron subvariants that are likely to be resistant to currently used anti-SARS-CoV-2 monoclonal antibodies (mAbs).
The subvariants BQ.1 and BQ.1.1 are likely resistant to bebtelovimab.
And the subvariants BA.4.6, BA.2.75.2, BA.5.2.6, BF.7, BQ.1, and BQ.1.1 are likely to be resistant to tixagevimab plus cilgavimab (Evusheld).
The anticipated loss of susceptibility is based on in vitro neutralization studies.
In this U.S. NIH statement issued on November 10, 2022, the COVID-19 Treatment Guidelines Panel provides interim recommendations for using bebtelovimab or Evusheld.
Other mAbs news is posted at PrecisionVaccinations/COVID-19.
Our Trust Standards: Medical Advisory Committee
